Companies /Healthcare

Novavax Inc

NASDAQ: NVAX Biotechnology
$7.96
▲ $0.00 (+0.00%) today
Markets closed · 11:38pm ET

24/7 Wall St. View

NVAX at a Glance

Valuation
Market cap
$1.3B
Profitability
Revenue (TTM)
$411.6M
Profit margin
-18.6%
EPS (TTM)
$-0.51
Price
52-week range
$6 – $13
Street target
$14.11
Earnings
Q3 2026 EPS
$-0.19
vs. $-0.35 est.
+45.1%

Headquartered in Gaithersburg, MD Fiscal year ends December NASDAQ: NVAX novavax.com

About Novavax

Novavax, Inc. is a vaccine company whose technology platform combines protein-based nanoparticles with its proprietary Matrix-M saponin-based adjuvant. Its strategy rests on three pillars: partnering its technology, targeted and capital-efficient R&D, and a lean operating model.

Its marketed products are the COVID-19 vaccine Nuvaxovid and the R21/Matrix-M malaria vaccine. Commercial leadership of Nuvaxovid has moved to partners:
- Sanofi leads in the U.S. and select markets under a co-exclusive license.
- Takeda covers Japan.
- Serum Institute of India co-formulates and fills product.

Novavax's revenue now comes from several partner-related sources:
- Supply sales of finished product and Matrix-M adjuvant to partners.
- Royalties: high teens to low twenties percent on Sanofi's Nuvaxovid sales, and high single digits to sub-teens percent on Sanofi CIC products.
- Milestones, including a pending $75 million technology-transfer milestone and a $225 million U.S. CIC launch milestone.
- R&D reimbursement and licensing deals with partners including Pfizer and Serum.

Its internal pipeline includes a preclinical C. difficile vaccine expected to enter the clinic as early as 2027. Novavax is also exploring Matrix-M in other infectious diseases and oncology to create further licensing opportunities. Updated

Revenue by Segment · Q3 2026
  1. Supply Sales38%
  2. Sanofi Licensing28%
  3. Other Partners Licensing16%
  4. Takeda Licensing10%
  5. Serum Licensing7%

NVAX Coverage

Frequently Asked Questions

What does Novavax do?

Novavax, Inc. is a vaccine company whose technology platform combines protein-based nanoparticles with its proprietary Matrix-M saponin-based adjuvant. Its strategy rests on three pillars: partnering its technology, targeted and capital-efficient R&D, and a lean operating model.

What is the NVAX stock price target?

The Wall Street consensus 12-month price target for NVAX is $14.11.